Paper Details

  1. Home
  2. Paper Details

Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis.

Author: CalcinariAlessandra, CastelettiSefora, CirioniOscar, GhiselliRoberto, GiacomettiAndrea, GuerrieriMario, KamyszElzbieta, KamyszWojciech, OrlandoFiorenza, RiminiMassimiliano, SilvestriCarmela, TocchiniMassimo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The amphibian peptide citropin 1.1, alone and in combination with tazobactam-piperacillin (TZP), showed efficacy in treating gram-negative sepsis in mice models. Both citropin 1.1 and TZP reduced lethality, but the combination was most effective in reducing plasma endotoxin, cytokine levels, and bacterial growth in blood and peritoneum.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Gram-negative sepsis ranks as the leading cause of death in intensive care units, and its incidence is increasing steadily and mortality rates has not changed much over recent decades. MATERIALS AND METHODS: We investigated the efficacy of the amphibian peptide, citropin 1.1 alone and i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jss.2010.03.055

データ提供：米国国立医学図書館（NLM）

Combating Gram-Negative Sepsis: A Multi-faceted Approach

This research explores the potential of citropin 1.1, an amphibian peptide, in treating gram-negative sepsis, a life-threatening infection. The study investigates the efficacy of citropin 1.1 alone and in combination with tazobactam-piperacillin (TZP), a commonly used antibiotic, in two mouse models of gram-negative sepsis. The authors highlight the increasing incidence and mortality rates associated with gram-negative sepsis, emphasizing the need for new therapeutic approaches.

A Powerful Partnership: Combining Citropin 1.1 and Tazobactam-Piperacillin

The results demonstrate that citropin 1.1, when combined with TZP, significantly reduced lethality, bacterial growth, and oxidative stress in both mouse models. This combination therapy proved to be more effective than either treatment alone, suggesting a synergistic effect. The researchers suggest that citropin 1.1's multifunctional properties, including its antioxidant and anti-inflammatory effects, contribute to its effectiveness in combating sepsis.

A New Frontier in Sepsis Treatment: Exploring Amphibian Peptides

This research opens up new possibilities for the treatment of gram-negative sepsis. The study's findings highlight the potential of citropin 1.1 as a valuable therapeutic agent, particularly in combination with antibiotics. The authors emphasize the need for further investigation to explore the clinical applications of citropin 1.1 and its potential to improve patient outcomes.

Dr.Camel's Conclusion

This research is like a camel caravan encountering a desert storm. Gram-negative sepsis is a dangerous and unpredictable enemy, but citropin 1.1, like a sturdy camel with its own unique defenses, can help us weather the storm. The combination therapy is like finding a hidden oasis in the middle of the storm – a place of refuge and healing. This research offers a glimmer of hope in the fight against sepsis.
Date :
  1. Date Completed 2012-01-06
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

20605608

DOI: Digital Object Identifier

10.1016/j.jss.2010.03.055

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.